Storrs, Erik P.
Chati, Prathamesh
Usmani, Abul http://orcid.org/0000-0001-5485-7323
Sloan, Ian
Krasnick, Bradley A.
Babbra, Ramandeep
Harris, Peter K.
Sachs, Chloe M.
Qaium, Faridi
Chatterjee, Deyali
Wetzel, Chris
Goedegebuure, S. Peter
Hollander, Thomas
Anthony, Hephzibah
Ponce, Jennifer
Khaliq, Ateeq M. http://orcid.org/0000-0001-5200-081X
Badiyan, Shahed
Kim, Hyun
Denardo, David G.
Lang, Gabriel D.
Cosgrove, Natalie D.
Kushnir, Vladimir M.
Early, Dayna S.
Masood, Ashiq
Lim, Kian-Huat http://orcid.org/0000-0002-2766-200X
Hawkins, William G.
Ding, Li
Fields, Ryan C. http://orcid.org/0000-0001-6176-8943
Das, Koushik K.
Chaudhuri, Aadel A. http://orcid.org/0000-0003-3115-3061
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (K08CA238711, 5P50CA196510, U2CCA233303, 5P50CA196510, 1U2CCA252981)
V Foundation for Cancer Research
Cancer Research Foundation
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 6 April 2023
Accepted: 26 September 2023
First Online: 19 October 2023
Competing interests
: E.S. and A.A.C. have patent filings related to cancer biomarkers. F.Q. has stock options in Centene, Gilead, and Horizon Therapeutics. H.K. has received research funding, travel accommodations, and honoraria from Varian Medical Systems and from ViewRay, and has consulted for Varian Medical Systems. W.G.H. is a member of the board of directors for Accuronix Therapeutics. A.A.C. has licensed technology to Droplet Biosciences, LiquidCell Dx, Tempus Labs, and Biocognitive Labs. A.A.C. has served as a consultant/advisor to Roche, Tempus, Geneoscopy, Illumina, Invitae, Myriad Genetics, NuProbe, Daiichi Sankyo, AstraZeneca, AlphaSights, DeciBio and Guidepoint. A.A.C. has received honoraria from Roche, Foundation Medicine, Agilent, and Dava Oncology. A.A.C. has stock options in Geneoscopy, research support from Roche, Illumina, and Tempus Labs, and ownership interests in Droplet Biosciences and LiquidCell Dx. No potential conflicts of interest were disclosed by the other authors.